Introduction
Failure of conventional chemotherapy in refractory acute myeloid leukemia (AML) is frequently linked to the expression of a multidrug resistance (MDR) phenotype. One of the most important mechanisms of MDR is mediated by the MDR gene-1 (mdr-1), [1] [2] [3] [4] which encodes a 170-kDa transmembrane glycoprotein known as permeability glycoprotein (P-gp). [5] [6] [7] [8] [9] The correlation between mdr-1 gene expression and poor treatment outcome is well documented in AML. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] There has thus been a remarkable interest in developing pharmacologic strategies for MDR reversal in vivo. Although several comparative studies with P-gp modulators have been limited by the unacceptable toxicities of available agents, recent clinical phase I/II studies have demonstrated the feasibility of this strategy. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] PSC 833 (Valspodar; Novartis Pharma Corporation, East Hanover, NJ, USA), a cyclosporine analog without immunosuppressive or nephrotoxic toxicity, is approximatively five-fold to 30-fold more potent than cyclosporine A (CsA) in vitro, and, unlike CsA, is a high-affinity noncompetitive inhibitor of P-gp. [40] [41] [42] A few studies investigating the use of PSC 833 in human malignancies have shown the improvement of clinical response in patients with AML, [30] [31] [32] [33] [34] [35] [36] as well as with other refractory malignancies. [37] [38] [39] Older and relapsed/refractory AML patients, however, are burdened by an unacceptable toxicity when treated with aggressive regimens, and schemes with low-toxic profile seem to be appropriate in these kinds of patients. A regimen of mitoxantrone and etoposide, with intermediate-dose cytarabine (MEC), has been shown to be effective, with acceptable toxicity, in relapsed or refractory AML. [43] [44] [45] [46] However, although complete remission rates in relapsed/refractory AML patients treated with a MEC regimen range from 39% to 44%, only 3% of patients are disease-free after 2 years, in part probably due to MDR. Therefore, addition of an MDR modulator such as PSC 833 to a mitoxantrone-etoposide-based regimen seemed a logical step. Encouraging results have been shown from very recent studies 30, 35 (comprising a partial, preliminary report of the present data 31 ) investigating the use of a regimen of mitoxantrone and etoposide, with or without intermediate-dose cytarabine. Chauncey et al 35 studied older patients with untreated AML and suggested that the addition of PSC 833 to a mitoxantrone-etoposide regimen for older patients with untreated AML is well tolerated but requires a reduction in mitoxantrone-etoposide dosing to avoid increased toxicity. In effect, grade III-IV hyperbilirubinemia according to WHO grading scale, as well as cerebellar dysfunction and paresthesias were frequently observed. Thus, appropriate dose reductions are required when these cytotoxic agents are coadministered with PSC 833 to avoid increased toxicity, because PSC 833 can affect the normal physiologic transport and excretion of cytotoxic agents that are substrates for P-gp. 47 This could be particularly important for heavily pretreated patients, such as relapsed-refractory AML.
Basing on this, we planned a phase I study to establish a safe and effective regimen consisting of mitoxantrone, etopo-
Patients and methods
The study was an open-label, multicenter, phase I dose-escalation study to determine the maximum tolerated dose of mitoxantrone in combination with etoposide and cytarabine when coadministered with PSC 833 in patients with poorprognosis AML. The study protocol was approved by the Institutional Review Boards of the participating hospitals. All patients provided written informed consent.
Patient population
Adult patients between 18 and 65 years of age with a diagnosis of AML by the French-American-British classification, 48 who had either failed to obtain a complete response to firstline induction therapy (ie, refractory patients) or were in first or subsequent relapse within 9 months of attaining CR, were enrolled. Refractory patients had to have received at least two cycles of an anthracycline-containing induction regimen before entry into this study. Other eligibility criteria included World Health Organization (WHO) performance status р2 and suitability for intensive chemotherapy in the opinion of the treating physician.
Criteria for exclusion included the following: documented central nervous system involvement; left ventricular ejection fraction Ͻ50%, as measured by cardiac radionuclide-gated blood pool scan; severe rhythm abnormalities; other severe cardiac dysfunction; serum creatinine у175 mol/l; serum bilirubin у2.5-fold the institutional upper limit of normal; positive hepatitis B surface antigen, a known history of hepatitis C, or HIV infection; known hypersensitivity to CsA; prior treatment with radiotherapy to the pelvis and/or spinal axis in the 4 weeks prior to study entry; and chronic granulocytic leukemia in blast cell crisis.
Chemotherapy treatment
All patients were scheduled to receive one or two identical induction cycles of a minimum duration of 21 days. For each of the first 6 days of the induction cycle(s), the patients received cytarabine at a fixed dose of 1.0 g/m 2 /day as a 6-h infusion and etoposide at a fixed dose of 30.0 mg/m 2 /day as a 1-h infusion. Mitoxantrone was administered as a bolus injection at 3.0 mg/m 2 /day in cohort 1 and 4.5 mg/m 2 /day in cohorts 2 and 3. PSC 833 was administered at a dose of 10 mg/kg/24 h CIV. On day 1, the continuous infusion was started concomitantly with a loading dose of 2 mg/kg given over 2 h. The continuous infusion of PSC 833 was given for 168 h (7 days) in cohorts 1 and 2, and for 144 h (6 days) in cohort 3. The duration of PSC 833 administration was shortened in cohort 3 because pharmacokinetic (PK) data indicated that PSC 833 levels remained Ͼ1000 ng/ml for 24 h after the completion of the continuous infusion.
Treatment in subsequent cycles depended on the patient's response to therapy in the prior induction cycle using previously established criteria for response. 49 If the bone marrow after the first induction cycle showed у25% blasts, and/or extramedullary disease was diagnosed, the patient was considered a treatment failure and treatment was discontinued. If
Leukemia the bone marrow after the first induction cycle showed between 5% and 25% blasts, and there were no signs of extramedullary disease, a second course of induction chemotherapy was given. If the bone marrow after the first or second induction cycle showed Ͻ5% blasts and no signs of extramedullary disease, the patient was to receive consolidation therapy after peripheral blood recovery (ie, absolute neutrophil count у1500 cells/ml and a transfusion-independent platelet count у100 000/ml).
Response criteria
Complete remission (CR) required adequate marrow cellularity with Ͻ5% of blasts documented at the preconsolidation evaluation, no peripheral blasts, an absolute neutrophil count у1500/l, platelet count у100 000/l, and no evidence of extramedullary leukemia. Partial remission (PR) required all criteria as in CR except that the bone marrow may have contained 5% to 25% blasts, or the bone marrow had Ͻ5% blasts, in the presence of moderate thrombocytopenia (50-100 000/l). Failure was defined as leukemia-associated or caused by early death (ie, within 30 days of completion of treatment). Leukemia-related causes of failure were refractory disease (inability to achieve hypoplasia despite one cycle of chemotherapy) and regrowth resistance, a term used to indicate cases in which Ͼ25% bone marrow blasts were noted on recovery despite adequate marrow hypoplasia having been achieved. 49 
Determination of maximum tolerated dose and doselimiting toxicity
This was an open-label, multicenter phase I dose-escalation study to determine the MTD of mitoxantrone and etoposide given in combination with fixed doses of PSC 833 and cytarabine in patients with poor-prognosis acute myelogenous leukemia. Patients were assigned sequentially to cohorts and dose escalation of either mitoxantrone or etoposide proceeded until the MTD could be defined. The anticipated dose range of mitoxantrone tested was 4-8 mg/m 2 /day and for etoposide 60-100 mg/m 2 /day. However, these planned dose ranges were subsequently modified in a protocol amendment, when information from a similar US study became available. 30 According to this trial, it was decided not to escalate the doses of mitoxantrone and etoposide above cumulated doses per induction cycle of 25 mg/m 2 and 250 mg/m 2 , respectively. The following algorithm was used to determine mitoxantrone or etoposide dose escalation:
• If 0/3 patients in any cohort experienced DLT, then escalation to the next cohort was allowed.
• If 1/3 patients in any cohort experienced DLT, then an additional three patients were enrolled. If no further DLT occurred, dose escalation to the next cohort continued.
• If Ͼ1 patient in any cohort experienced DLT there was no further dose escalation and the MTD of cytarabine, mitoxantrone and etoposide in combination with PSC833 was defined as the dose combination of the previous cohort.
The MTD was defined as the dose below the dose associated with DLT in 2/6 patients in the first cycle.
Dose-limiting toxicities were based on NCIC Expanded Common Toxicity Criteria, divided into hematological and non-hematological types and defined as follows.
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Non-hematological DLT:
CTC grade 3/4 non-hematological toxicity occurring up to 14 days after cessation of PSC833 infusion but excluding nausea, vomiting, alopecia, infectious causes and grade 3 reversible cerebellar dysfunction. Grade 4 hyperbilirubinemia was considered dose limiting if it was the only reason for treatment discontinuation, ie resulting in a delay of treatment Ͼ7 days.
The definitions of cerebellar dysfunction used in the NCIC CTC are ill-suited to classifying the actual dysfunction observed in patients, therefore the following revised definitions for cerebellar toxicity were used.
Grade 1: Slight subjective sense of incoordination. No difficulty walking. Physical examination normal or equivocally normal. Grade 2: Definite subjective incoordination on walking, but able to walk without assistance. On examination, broad-based gait and/or mild dysdiadochokinesias and difficulty walking heel-to-toe. Grade 3: Unable to walk without assistance from another person or a walker. On examination, markedly abnormal gait and inability to walk heel-to-toe. Grade 4: Unable to walk, because of incoordination, even with assistance.
Hematological DLT:
Hypoplastic death during the first cycle occurring between 34 and 45 days from the start of chemotherapy with no evidence of persisting AML (if disease was still evident hypoplastic death was not dose limiting); neutropenia after the first cycle (only if patient was in CR) defined as ANC Ͻ0.5 × 10 9 /l for Ͼ45 days after it was first measured; thrombocytopenia after the first cycle (only if patient was in CR) defined as platelets Ͻ20 × 10 9 /l for Ͼ45 days after it was first measured.
Pharmacokinetic analysis
The pharmacokinetics of PSC 833, mitoxantrone, and etoposide were assessed in induction cycle 1 and during consolidation. In induction cycle 1, plasma concentrations of etoposide and mitoxantrone were determined during concomitant administration of PSC 833. In the consolidation cycle a PK profile was performed on day 1 in the absence of PSC 833. Blood samples (2 ml) for PK analysis of PSC 833 were drawn on day 1 just after completing the loading dose and before starting CIV, and thereafter at the same time daily on each day of PSC 833 administration in the induction cycle. The PSC 833 concentration in whole blood was determined using a radioimmunoassay as previously published. 50 Blood samples (5 ml) for measurement of etoposide and mitoxantrone plasma concentrations were taken just before drug administration and at 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 h (this last sample only in the induction cycle) after the start of administration. Plasma levels were assayed using high-performance liquid chromatography as previously described. 51, 52 The plasma concentration-time data for etoposide and mitoxantrone were analyzed separately by standard noncompartmental methods. The following parameters were derived: area under the curve (AUC) over a 24-h dosing interval by trapezoidal summation; total body clearance (CL = Dose/AUC); and distribution volume associated with the terminal phase (V z = CL/lambda) and terminal disposition rate constant (lambda) by log-linear regression of the terminal portion of the profile. The corresponding half-life (t 1/2 ) was calculated as t 1/2 = ln 2 /lambda.
Determination of P-gp expression and function
Bone marrow aspirates (3 ml) from the sternum or the posterior iliac crest were collected at diagnosis and stored at 0°to 4°C in 2 ml of Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Paisley, UK) containing 5000 IU of heparin. Mononuclear bone marrow cells were collected by centrifugation over Lymphoprep (Nycomed, Oslo, Norway) and suspended at a concentration of 4 × 10 6 cells/ml in DMEM supplemented with 10% fetal calf serum and gentamycin. P-gp expression was determined by staining with monoclonal antibodies against P-gp: MRK16 (Kamiya Biomedical Company, Seattle, WA, USA) at a concentration of 10 g/ml. An isotypematched murine immunoglobulin (Ig)G2a control antibody (Sigma, St Louis, MO, USA) was used at a concentration of 10 g/ml. Cell-bound antibodies were detected using fluorescein isothiocyanate-conjugated rabbit anti-mouse antibodies (DAKO, Glostrup, Denmark). Fluorescence was measured using a FACScalibur (Becton Dickinson, San Jose, CA, USA). Results were expressed as the ratio of cell-associated fluorescence of cells incubated with the anti-P-gp antibody to the mean of cell-associated fluorescence of cells incubated with the nonspecific control antibody as previously described. 18 Function of P-gp was measured by incubating cells for 1 h at 37°C at 5% CO 2 in the presence or absence of 2 m PSC 833, followed by incubation with 200 ng/ml rhodamine-123 (Sigma). Fluorescence was measured using a FACScalibur. Results are expressed as the ratio of the mean intracellular rhodamine fluorescence of cells exposed to PSC 833 to the mean intracellular fluorescence of cells not exposed to PSC 833.
The drug-sensitive cell line RMPI 8226 S and the drugresistant variant 8226 D6, kindly provided by Dr W Dalton (H Lee Moffitt Cancer Center, Tampa, FL, USA), were used as negative and positive controls, respectively, for P-gp function and expression assays. In the P-gp function assay, the mean ratio of rhodamine-123 fluorescence was 0.91 ± 0.07 for the negative control vs 7.03 ± 4.69 for the positive control (mean ± standard deviation, n = 59). Patient bone marrow samples were considered positive for P-gp function when the ratio of rhodamine-123 fluorescence was above 1.05, which was significantly greater than the negative control (P Ͻ 0.05, two-sided t-test). For P-gp expression, the mean MRK16/IgG2a ratios were 1.32 ± 0.29 for the negative control vs 30.23 ± 5.01 for the positive control (mean ± standard deviation, n = 59). Patient samples were considered positive for Pgp expression, if the ratio of P-gp fluorescence was above 1.65 (P Ͻ 0.05, two-sided t-test).
Results
Twenty-three patients were enrolled in the study. The majority of patients (65%) were male and 70% were Ͻ50 years of age (mean age, 41.6 years; range, 18-69 years). Eight patients had primary refractory disease, 14 patients had relapsed within 6 to 9 months of achieving CR, and one patient had relapsed 11 months after CR. Among the 15 relapsed patients, 13 were in first relapse and two were in second relapse. Six patients had AML secondary to myelodysplastic syndrome. Summary 767 statistics by cohort are presented in Table 1 . The cohorts were comparable with respect to baseline demographic and clinical characteristics.
Overall, 20 patients went off study before consolidation: 17 after the first induction cycle and three after the second induction cycle. Eleven of 23 (48%) patients discontinued due to treatment failure (excluding death). Three patients discontinued due to adverse events (one patient in cohort 2 due to grade 4 hyperbilirubinemia, and two patients in cohort 3 due to persistent aplasia and abnormal liver function). One patient in each cohort died during the study as a result of cardiorespiratory arrest (cohort 1), gastrointestinal hemorrhage (cohort 2), and pneumonia (cohort 3). Three patients withdrew their consent to further treatment; one was in CR after two induction cycles and did not receive a consolidation cycle; the second one discontinued the study treatment in order to receive a bone marrow transplant, and was reported later on to be in CR; the last one discontinued after the second induction cycle as a protocol violation, the reason stated by the investigator being persistent leukopenia and thrombocytopenia.
Adverse events
Dose-limiting toxicities were grade 4 oral mucositis (one patient in cohort 2) and grade 4 hyperbilirubinemia with grade 3 raised transaminases (one patient in cohort 3). The incidence of hematologic toxicity did not differ from that expected in this patient population receiving the full-dose MEC regimen without PSC 833, and none was dose limiting. Fever, infection, bilirubinemia/jaundice, mucositis/stomatitis, rash, diarrhea, and nausea were the most frequently observed nonhematologic toxicities in the three cohorts (Table 2) .
Bilirubinemia/jaundice was a frequently reported adverse event, occurring in a total of 13 (57%) patients. Eleven (48%) patients experienced grade 3 (ie, 3× IULN) or 4 hyperbilirubinemia (ie, Ͼ10× ULN), and based on the laboratory data, at least one grade 3 or 4 bilirubin value was recorded for 16 (70%) patients and at least one grade 4 value was recorded for 11 (48%) patients. Five (22%) patients had clinically significant grade 4 hyperbilirubinemia; in one patient, this resulted from a massive gastrointestinal hemorrhage, which was an aplasia-related event, and from which the patient died 15 days after the start of treatment. The other four cases were possibly related to treatment. In these patients, grade 4 hyperbilirubinemia started on days 2 to 9, reached a maximum value of 4× to 21× the upper limit of normal on days 8 to 24, and subsequently improved. Two of these patients experi- enced prolonged (ie, Ͼ16 days) grade 4 bilirubinemia, but this resulted in serious adverse event reporting, DLT and discontinuation of only one patient in cohort 3 who also had raised transaminases. Nevertheless, this patient achieved CR and was one of the two surviving patients at the last follow-up visit at 18 months. In the other two patients, the prolonged hyperbilirubinemia did not impact their clinical course and was not considered a DLT. The fourth patient in cohort 2 experienced prolonged hyperbilirubinemia that did not remain consistently at grade 4, but ultimately resulted in study discontinuation of that patient; however, this was not classified as a DLT. Mild to moderate cerebellar toxicity resulting in ataxia or paresthesia was reported in six (26%) and five (22%) patients, respectively; no patient experienced grade 3 or 4 cerebellar toxicity. Paresthesia led to interruption of the PSC 833 infusion for 22 h in one patient, but otherwise neither ataxia nor paresthesia was severe enough to be dose limiting. A conservative evaluation of the patients with possible ataxia used the preferred adverse event terms of dizziness, cerebellar syndrome, and gait abnormal, and these were included in the ataxia group.
Response
Overall, six (26%) patients achieved CR, including the one patient who withdrew after only one induction cycle for a bone marrow transplant (Table 3 ). In addition, one patient achieved partial remission. Among 14 patients who failed chemotherapy, 10 patients had absolute or relative drug resistance, three patients had marrow regeneration failure, and one patient died with indeterminate response to therapy. Two additional patients died on study and their response to therapy was not evaluable. Three patients, all in cohort 1, achieved CR after the first cycle and received a subsequent consolidation cycle. One patient in cohort two was in CR after two induction cycles and did not receive a consolidation cycle. Two additional patients, one each in cohorts 2 and 3, achieved CR after the first induction cycle and refused further treatment. The median overall survival was 4 months. The 1- (14) 3 (13) year event-free and overall survival rates were 17% and 26%, respectively.
P-gp expression and function
Sixteen (70%) patients were assessed for P-gp expression, and 12 (52%) patients were assessed for P-gp function at baseline; seven patients were not evaluable for either (Table 4) . Overall, 13 of 16 assessable patients tested positive for P-gp expression and/or function, and four patients tested positive for both expression and function. Five of 13 (38%) patients who tested positive for P-gp expression and/or function achieved CR. Three patients were negative for both P-gp expression and function, but none of these patients responded to treatment. One patient who was unevaluable for P-gp expression/function achieved CR.
Pharmacokinetics
Blood concentrations of PSC 833 were measured daily in 21 patients. After the loading dose, levels ranged from 1400 to 8900 ng/ml. Serum levels of PSC 833 were well above 1000 ng/ml in all patients, a concentration shown to reverse MDR in resistant cell lines in vitro. 36 Overall mean values up to the last day of PSC 833 dosing in all cohorts are shown in Figure 1 .
The terminal elimination phase of etoposide was defined. 
Figure 1
Mean (± standard deviation) whole blood concentrations of PSC 833. Number of patients is indicated at each data point.
Table 5
Selected pharmacokinetic parameters of etoposide (cycle 1 only) the observation that concurrent administration of PSC 833, even at low doses, has a profound effect on etoposide CL. 53 Descriptive statistics of selected PK parameters for etoposide are given in Table 5 . The PK of mitoxantrone was highly variable between patients. Only two patients had PK sampling for mitoxantrone and etoposide in both the induction and the consolidation cycles. Thus, a within-study comparison of the PK parameters of mitoxantrone and etoposide with and without concurrent PSC 833 was not possible. 
Pharmacokinetic/Pharmacodynamic relationship
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AUC of these two agents and response to therapy was apparent.
Discussion
Reversal of MDR is clearly an important goal in patients with relapsed and refractory AML. The clinical challenge when using MDR modulators such as PSC 833 is the PK interactions between PSC 833 and chemotherapy agents, such as etoposide, that are substrates for P-gp. The results of this and the previously reported ECOG trial have established a safe and well-tolerated modified MEC regimen that has activity in this group of poor-prognosis patients.
In particular, regarding poor-risk AML patients, Estey et al 54 have recently proposed to place these patients in four categories that correlated their responses to conventional treatment with presenting clinical features. These patients were categorized as being in one of four prognostic risk groups, based on their treatment history. Group 1 patients had expected CR rates of approximately 70% (patients with a first CR lasting Ͼ2 years being treated with conventional therapy); group 2 patients had expected CR rates of approximately 40% (patients with a first CR duration of 1 to 2 years being treated with conventional treatment); group 3 patients had expected CR rates of approximately 10 to 20% (patients with a first CR lasting Ͻ1 year, or with no initial CR, who were receiving their initial salvage attempt with conventional treatment); and group 4 patients had expected CR rates of Ͻ1% (patients with an initial CR Ͻ1 year, or with no initial CR, who were receiving a second or subsequent salvage regimen, having not responded to a first salvage attempt with conventional drugs). The patient population studied here contains only poor-prognosis AML patients, and is virtually categorized as being in the very poor prognostic risk groups 3 and 4 ( Table 1) . Of the 23 patients enrolled in the current study, 21 (91%) would fall into group 3 and two (9%) would fall into group 4. Therefore, despite these poor-risk features, the observed CR rates (22%) were higher than expected for this patient population, as were the CR rates reported from other studies investigating the use of PSC 833 to modulate MDR in poor-prognosis relapsed or refractory AML patients. [30] [31] [32] [33] [34] [35] [36] The observed CR rates achieved with this regimen are encouraging and provide a rationale for further investigation of this regimen in relapsed or refractory AML patients. Previously, Advani et al 30 reported a 32% CR rate in 37 evaluable, poor-risk (groups 3 and 4), relapsed/refractory AML patients treated with a 5-day MEC plus PSC 833 regimen on the ECOG protocol. Among this cohort were 27 patients with de novo AML and 10 patients with secondary AML. The 22% CR rate reported here compares favorably with the ECOG experience and with reports from studies investigating intermediate-and high-dose cytarabine-containing regimens. 55 Taken together, these studies show the antileukemic effectiveness of the PSC-MEC regimen suggesting its promising activity in relapsed and refractory AML patients who have a low probability of response and long-term disease-free survival.
The final doses of mitoxantrone and etoposide determined in this trial were consistent with the final doses established in a similar phase I/II ECOG study in poor-risk AML patients, in whom a 5-day MEC plus PSC 833 regimen was investigated. . The PK analysis of the ECOG study indicated that in the presence of PSC 833 there was a 57% decrease in the CL of etoposide, and the mean t 1/2b of mitoxantrone was increased 1.8-fold compared with historical controls. In the present study, the mean etoposide CL value was 0.63 l/h/m 2 , which represents a 50% decrease in the expected etoposide CL of approximately 1.2 l/h/m 2 reported in the literature in the absence of PSC 833. [56] [57] The high degree of concordance between published studies indicates that the PK interaction between PSC 833 and etoposide is highly predictable, and that concurrent PSC 833, even at low doses, has a profound effect on etoposide CL. [32] [33] [34] [35] 37, 39 With regard to the PK analysis of mitoxantrone, the sampling schedule during the first 2 h was not dense enough to determine the first disposition phases of mitoxantrone, but the observed t 1/2b fell well within the range reported in the literature. 58 Therefore, based on cumulative clinical experience with PSC 833, it is now possible to institute appropriate dose reductions in the scheduled doses of etoposide and mitoxantrone. These findings, plus the tolerability of the drug, indicated effective dosing of PSC with this regimen.
Administration of PSC 833 by CIV was well tolerated in this study and achieved target blood levels capable of modulating P-gp in vitro. Approximately 25% of patients reported mild to moderate ataxia or paresthesia, but no patients experienced grade 3 or higher ataxia. The primary DLTs observed in this study were nonhematologic (mucositis and hyperbilirubinemia). Clinically significant grade 4 hyperbilirubinemia, possibly related to treatment, was observed in four patients but was considered a DLT in only one patient. In two of these patients hyperbilirubinemia was reversible, was not accompanied by elevated liver enzymes, and had no major impact on the patients' clinical course; therefore, this toxicity was considered acceptable in the context of the regimen and patient population. The cause of hyperbilirubinemia is likely to be multifactorial and to include the effects of hemorrhages, other coexistent medical conditions, and competition between PSC 833, concomitant chemotherapy agents, and bilirubin for the cytochrome P-450 3A metabolic pathways in the liver.
Although the predictive value of P-gp expression and inhibitable P-gp-mediated rhodamine-123 efflux as an independent marker of treatment failure has not been clearly established, studies to date suggest that P-gp expression is an important determinant of therapeutic outcome in patients with relapsed or refractory AML, and that reversing MDR due to Pgp expression may benefit patients by improving therapeutic response to established cytotoxic regimens. Despite a number of agents inhibiting the function of P-gp blocking efflux of drugs from the intracellular compartment [59] [60] [61] (ie verapamil, cyclosporine and quinine, that are effective in vitro), their clinical use is limited by side-effects that contribute to the relatively poor clinical outcome of these patients. In addition, recent randomized studies 62, 63 using quinine as an MDR modulator plus intensive chemotherapy for AML post MDS and high-risk MDS patients showed that, instead of increasing CR rate and disease-free survival in patients considered to be P-gp positive, quinine had no effect on response rate and survival of those who were considered P-gp negative.
Bearing this in mind, two points have to be underlined: (1) the ability that MEC regimen plus PSC 833 has to produce CR in patients with an MDR phenotype (five of 13 (38%) P-gppositive patients achieved CR); (2) PSC-833 is relatively free of side-effects at doses that are adequate to block P-gp function in vitro and to reverse the MDR phenotype.
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Nevertheless, clinical randomized studies are necessary to clarify the impact of PSC on therapy of poor-risk AML patients.
In conclusion, we have demonstrated that with appropriate dose modifications based on the predictable PK interactions between PSC 833 and chemotherapy agents, PSC 833 can be safely combined with a modified MEC regimen in patients with relapsed or refractory AML. Moreover, serum levels of PSC 833 capable of reversing MDR were achieved and resulted in a substantial rate of CR in a patient population with a low probability of CR, including P-gp-positive patients. These encouraging results warrant further investigation of this regimen.
